TherapeuticsMD, Inc. (TXMD) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 46 institutional investors hold a position in TherapeuticsMD, Inc. (NASDAQ:TXMD).

• These investors collectively held 21.9% of the company's total shares outstanding in September 2025, down from 29.5% in June 2025.
• Institutional share ownership changed by 1.50% QoQ, while the number of institutional owners saw an increase of 21.05% YoY.
• The latest 13F cycle for TherapeuticsMD reveals that of 46 total investors, 10 funds grew their exposure, whereas 11 reduced theirs and 25 made no changes.
• This class of investors increased its holdings in TherapeuticsMD to 3.30Mn shares for the 13F-cycle ending September 2025, up by 48.70K shares quarter on quarter, and down 75.89K shares year over year.
• The top institutional stake in TherapeuticsMD as of September 30, 2025 belongs to Rubric Capital Management LP, which owns 1.19Mn shares, or 7.90% of the company.
• Among the most significant buyers of TherapeuticsMD during September 2025 were CITADEL ADVISORS LLC (34.27K), RENAISSANCE TECHNOLOGIES LLC (20.60K), TWO SIGMA SECURITIES, LLC (1.53K), BARCLAYS PLC (44), OSAIC HOLDINGS, INC. (36).
• Leading sellers of TherapeuticsMD stock in September 2025 included UBS Group AG (4.14K), VANGUARD GROUP INC (2.17K), MORGAN STANLEY (638), BANK OF AMERICA CORP /DE/ (414), CITIGROUP INC (202).
• The top 10 institutional holders of TherapeuticsMD for the quarter ending September 2025 included Rubric Capital Management LP (1.19Mn), Clearline Capital LP (635.22K), VANGUARD GROUP INC (376.83K), Tejara Capital Ltd (344.20K), ADAR1 Capital Management, LLC (209.21K), MORGAN STANLEY (130.57K), BlackRock, Inc. (116.13K), GEODE CAPITAL MANAGEMENT, LLC (109.08K), RENAISSANCE TECHNOLOGIES LLC (35.50K), CITADEL ADVISORS LLC (34.27K).